Showing 821-830 of 2394 results for "".
- MDA Provides COVID-19 Recommendations for People with Neuromuscular Conditions that Also Apply to Other Neurologic Conditionshttps://practicalneurology.com/news/mda-provides-covid-19-recommendations-for-people-with-neuromuscular-conditions-that-also-apply-to-other-neurologic-conditions/2469188/The Muscular Dystrophy Association (MDA) has provided recommendations for people in the neuromuscular community regarding the current COVID-19 pandemic. Noting that current guidelines from public health agencies focus on travelers, specific age group
- FDA Rejects Application for Gene Therapy for Hunter Syndromehttps://practicalneurology.com/news/fda-rejects-application-for-gene-therapy-for-hunter-syndrome/2485648/The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for RGX-121 (clemidsogene lanparvovec; REGENXBIO, Rockville, MD), meaning that, at this time, the FDA will not approve the investigational gene therapy for mucopolysaccha
- Director of the National Institute of Neurological Disorders and Stroke Oustedhttps://practicalneurology.com/news/director-of-the-national-institute-of-neurological-disorders-and-stroke-ousted/2485145/The contract for Walter Koroshetz, MD, as Director of the National Institute of Neurological Disorders and Stroke (NINDS) has not been renewed, ending his leadership of the institute after 10 years. Dr. Koroshetz’s departure comes despite a positive internal review and a recommendation for reappo
- Prof. Ludwig Kappos Recognized for His Lifetime Achievement in Multiple Sclerosis Research at ECTRIMS 2025https://practicalneurology.com/news/prof-ludwig-kappos-recognized-for-his-lifetime-achievement-in-multiple-sclerosis-research-at-ectrims-2025/2483561/At the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Ludwig Kappos, MD, Dipl Psych, FEAN, FAAN was recognized as the recipient of the 2025 Charcot Award. According to ECTRIMS, the Charcot Award, which is presented by the Multiple Sclerosis Int
- Studies Evaluate the Reweighting of Parkinson Disease Assessment Tools for Improved Sensitivity and Efficiencyhttps://practicalneurology.com/news/studies-evaluate-the-reweighting-of-parkinson-disease-assessment-tools-for-improved-sensitivity-and-efficiency/2474181/Reweighting the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and other measures may provide greater sensitivity and responsiveness in assessing motor and functional decline in people with Parkinson disease (PD), according to the results of 2 studies presented at
- Continuous, Subcutaneous Apomorphine Infusion Device Approved for Parkinson’shttps://practicalneurology.com/news/continuous-subcutaneous-apomorphine-infusion-device-approved-for-parkinsons/2473778/The Food and Drug Administration (FDA) has approved the wearable Onapgo (apomorphine hydrochloride; Supernus Pharmaceuticals, Rockville, MD) subcutaneous injection device to treat motor fluctuations in adults with advanced Parkinson disease (PD). Onapgo enables continuous apomorphine infusion dur
- National Institutes of Health Allege Research Misconduct by Prominent Neuroscientist and Investigator of α-Synuclein in PD and ADhttps://practicalneurology.com/news/nih-alleges-research-misconduct-by-prominent-neuroscientist-and-investigator-of-a-synuclein-in-pd-and-ad/2470601/Eliezer Masliah, MD, director of the National Institutes of Aging (NIA) neuroscience division, has been accused of research misconduct via the falsification, duplication, and manipulation of images, particularly western blot images. Much of Dr. Masliah’s work focuses on the role of &al
- New Drug Application Is Submitted for Vamorolone for Treating Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/new-drug-application-is-submitted-for-vamorolone-for-treating-duchenne-muscular-dystrophy/2470058/The submission of a new drug application (NDA) to the Food and Drug Administration (FDA) has been completed, seeking priority review for vamorolone (Santhera Pharmaceuticals, Prattein, Switzerland; and ReveraGen BioPharma, Rockville, MD) for the treatment of Duchenne muscular dystrophy (DMD).&nbs
- Phenogroups of Migraine Identified With Artificial Intelligence-Guided Topologic Mappinghttps://practicalneurology.com/news/phenogroups-of-migraine-identified-with-artificial-intelligence-guided-topologic-mapping/2469941/Migraine is increasingly as a as a heterogeneous disorder, with a wide variety of headache characteristics, associated symptoms, and treatment responses. In a study presented at the American Headache Society meeting in Denver, CO June 9-12, 2022, Chia-Chun Chiang, MD, senior assoc
- Quest for Alzheimer Disease Treatments Continueshttps://practicalneurology.com/news/quest-for-alzheimer-disease-treatments-continues/2469577/The quest for effective treatment of Alzheimer disease (AD) continues as phase 2B and 3 clinical trials meet major milestones. Enrollment is complete for a trial of once-daily low dose of the antiseizure medication levetiracetam (AGB101; AgeneBio, Baltimore, MD) for treatment of a